Cognitive markers of preclinical and prodromal Alzheimer's disease in Down syndrome.

ABSTRACT:

Introduction

Down syndrome (DS) is associated with an almost universal development of Alzheimer's disease. Individuals with DS are therefore an important population for randomized controlled trials to prevent or delay cognitive decline, though it is essential to understand the time course of early cognitive changes.

Methods

We conducted the largest cognitive study to date with 312 adults with DS to assess age-related and Alzheimer's disease-related cognitive changes during progression from preclinical to prodromal dementia, and prodromal to clinical dementia.

Results

Changes in memory and attention measures were most sensitive to early decline. Resulting sample size calculations for randomized controlled trials to detect significant treatment effects to delay decline

SUBMITTER: Startin CM 

PROVIDER: S-EPMC6374283 | biostudies-literature | 2019 Feb

REPOSITORIES: biostudies-literature